Unlearn

Unlearn is a technology company advancing artificial intelligence to eliminate trial and error in medicine by innovating advanced machine learning methods to leverage generative AI in forecasting patient outcomes, focusing on clinical trials. Founded in 2017 and headquartered in San Francisco, Unlearn develops AI-generated digital twins of trial participants to enable smaller and more efficient clinical trials. The company has raised venture capital from top-tier investors and completed a $50 million Series C in January 2024. Unlearn emphasizes ambitious, disciplined, gritty, receptive, storytelling, and team-oriented culture.